NCT04085887: Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1|Phase 2
Drug Category: Other, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 6 Months to 25 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Patients must eligible for surgical resection
Exclusions: Patients older than 25 years of age

Comments are closed.

Up ↑